The current front-line therapeutic options for advanced HCC have long included sorafenib, a multikinase inhibitor, and have more recently been expanded to include lenvatinib, another multikinase inhibitor, and the combination of atezolizumab/bevacizumab, comprising an immune checkpoint inhibitor (ICI) and anti-VEGF-A antibody. This evidence concerns the gene VEGFA and hepatocellular carcinoma.